AKBA Stock Analysis: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$0.85
-0.01 (-0.95%)
▼
5d:
-1.7%
30d:
-33.45%
90d:
-15.66%
WAIT
LOW Confidence
Analysis Updated: Aug 18, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AKBA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AKBA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $0.85, which is considered oversold relative to its 30-day fair value range of $0.97 to $1.38. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.3) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $0.81, while resistance sits at $1.35.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $3.80 (+346.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $0.81, while resistance sits at $1.35.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $3.80 (+346.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.97 -
$1.38
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
Protect Your Profits
Holding AKBA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 346.1% below Wall St target ($3.80)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.97 -
$1.38
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.81
Resistance Level
$1.36
Current Trend
Downtrend
Technical data as of
Aug 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.26
Wall Street Target
$3.80
(+346.1%)
Revenue Growth (YoY)
-21.4%
Profit Margin
-13.5%
PE vs Historical
-4.3 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: August 18, 2026 6:31 PM ET
Data refreshes hourly during market hours. Next update: 7:31 PM
Data refreshes hourly during market hours. Next update: 7:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
John P Butler
BUY
69270 shares
2026-03-04
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$653 | 61 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 49 HOLD |
|
ALKS
Alkermes Plc |
BUY
15 analysts |
$56 | 68 BUY |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
